Characterization of Statin Dose Response in Electronic Medical Records

[1]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[2]  Christopher G. Chute,et al.  The absence of longitudinal data limits the accuracy of high-throughput clinical phenotyping for identifying type 2 diabetes mellitus subjects , 2013, Int. J. Medical Informatics.

[3]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[4]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[5]  Farzad Mostashari,et al.  Achieving meaningful use of health information technology: a guide for physicians to the EHR incentive programs. , 2012, Archives of internal medicine.

[6]  R. Wilke,et al.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. , 2012, Pharmacogenomics.

[7]  P. Caraballo,et al.  Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus , 2012, J. Am. Medical Informatics Assoc..

[8]  A. Guttmacher,et al.  Genomics, Health Care, and Society , 2011 .

[9]  Simon Cawley,et al.  Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array. , 2011, Genomics.

[10]  Russell A. Wilke,et al.  Genetics and variable drug response. , 2011, JAMA.

[11]  D. Roden,et al.  The Emerging Role of Electronic Medical Records in Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[12]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[13]  Joshua C Denny,et al.  Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records , 2010, Genetics in Medicine.

[14]  Özlem Uzuner,et al.  Extracting medication information from clinical text , 2010, J. Am. Medical Informatics Assoc..

[15]  Olle Melander,et al.  From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus , 2010, Nature.

[16]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[17]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[18]  R. Baron,et al.  Meaningful use of health information technology is managing information. , 2010, JAMA.

[19]  C. McCarty,et al.  Biobanking and pharmacogenomics. , 2010, Pharmacogenomics.

[20]  Melissa A. Basford,et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.

[21]  Paul T. Williams,et al.  Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations , 2010, PloS one.

[22]  G. Nichols,et al.  Comparison of evidence-based versus non-evidence-based pharmacotherapy on the risk of cardiovascular hospitalization and all-cause mortality among patients with established cardiovascular disease. , 2010, The American journal of cardiology.

[23]  George Hripcsak,et al.  Accelerating the use of electronic health records in physician practices. , 2010, The New England journal of medicine.

[24]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[25]  D. Cox,et al.  Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort , 2009, Circulation. Cardiovascular genetics.

[26]  Norman Fost,et al.  Community consultation and communication for a population‐based DNA biobank: The Marshfield clinic personalized medicine research project , 2008, American journal of medical genetics. Part A.

[27]  Chengfeng Zhao,et al.  Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. , 2008, Basic & clinical pharmacology & toxicology.

[28]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[29]  B. Spiegelman,et al.  PRDM16 controls a brown fat/skeletal muscle switch , 2008, Nature.

[30]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[31]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[32]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[33]  Richard L Berg,et al.  Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. , 2007, Basic & clinical pharmacology & toxicology.

[34]  S. Rogers,et al.  A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. , 2007, Clinical therapeutics.

[35]  Feng Lin,et al.  Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. , 2006, The American journal of cardiology.

[36]  C. McCarty,et al.  Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. , 2005, Personalized medicine.

[37]  Russell A Wilke,et al.  Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage , 2005, Pharmacogenetics and genomics.

[38]  Peggy L. Peissig,et al.  Study of Effect of Drug Lexicons on Medication Extraction from Electronic Medical Records , 2004, Pacific Symposium on Biocomputing.

[39]  Jocelyn Kaiser,et al.  Population Databases Boom, From Iceland to the U.S. , 2002, Science.

[40]  R. Krauss,et al.  Differences in receptor binding of LDL subfractions. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[41]  R. Krauss,et al.  Cardiovascular pharmacogenomics. , 2011, Circulation research.

[42]  K. Hudson.  Genomics, health care, and society. , 2011, The New England journal of medicine.

[43]  B. J. Gersh.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[44]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[45]  J. Ordovás,et al.  CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. , 2004, The American journal of cardiology.